Glucosio Diaco

Glucosio Diaco is an intravenous solution that contains glucose monohydrate as its active ingredient. It is supplied in a sterile liquid form for parenteral administration, with the specific concentration not disclosed, and is marketed in the European Union as a prescription‑only product. The product is intended for use by healthcare professionals in hospital or clinical settings to provide an immediate source of carbohydrate energy and fluid support.

Glucosio Diaco is used in clinical practice to address conditions where rapid carbohydrate supplementation or fluid replacement is required. Its intravenous delivery allows precise control of glucose intake.

- Treatment of acute hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to eat or absorb nutrients enterally. - Provision of an energy source during peri‑operative fasting periods. - Support of fluid balance in patients receiving intravenous therapy. - Adjunctive therapy for electrolyte or mineral solutions requiring an energy substrate.

Glucosio Diaco may be associated with a range of physiological responses following intravenous infusion. Reported events are categorized by frequency and clinical significance.

Common: - Transient increase in blood glucose level. - Mild infusion site irritation or erythema. - Nausea or mild abdominal discomfort. - Headache or dizziness during rapid administration.

Serious: - Severe hyperglycemia requiring medical intervention. - Allergic reaction such as urticaria, rash, or angioedema. - Electrolyte imbalance, particularly hyponatremia or hyperkalemia. - Volume overload leading to pulmonary edema in susceptible patients.

When prescribing Glucosio Diaco, clinicians should evaluate patient‑specific factors and monitor relevant parameters to minimize risk.

- Verify baseline blood glucose and adjust infusion rate accordingly. - Use caution in patients with diabetes mellitus or impaired insulin response. - Assess renal and cardiac function before large‑volume administration. - Avoid rapid infusion in neonates and infants due to risk of hyperosmolar injury. - Monitor electrolytes, especially sodium and potassium, during therapy. - Discontinue or reduce infusion if signs of fluid overload appear.

Glucosio Diaco can interact with other agents that affect glucose metabolism, fluid balance, or electrolyte status. Interactions are grouped by recommended clinical approach.

Avoid: - Concurrent use of high‑dose insulin without glucose monitoring. - Co‑administration with other hypertonic carbohydrate solutions. - Simultaneous infusion of potassium‑rich solutions without electrolyte checks.

Use with caution: - Diuretics that may predispose to electrolyte disturbances. - Corticosteroids, which can increase blood glucose levels. - Beta‑adrenergic agonists that may mask hypoglycemia symptoms.